The efficacy of high-dose cabergoline treatment of prolactinomas resistant to standard doses: a clinical observation
Zilya A. Kalmykova,
Svetlana Y. Vorotnikova,
Natalia S. Fedorova,
Larisa K. Dzeranova,
Ekaterina A. Pigarova,
Aleksandr V. Vorontsov https://doi.org/10.14341/omet10243
Abstract
Hyperprolactinemia (HP) is one of the most common neuroendocrine disorders. In 60% of cases, pathological HP is caused by pituitary prolactin-secreting adenoma. Therapy with agonists of dopamine type 2 receptors (D2 receptor agonists) is a method of choice for the treatment of pathological HP which allows to achieve prolactin normalization and reduction of pituitary adenoma in most cases. However, 15-20% of patients are resistant to D2 receptor agonists, and the question of overcoming this resistance is highly relevant. Different approaches are considered to solve this problem, one - is to increase the dose of D2 receptor agonists up to the maximally tolerated. In this article, we present a clinical observation of a patient with a partial resistance to D2 receptor agonists who demonstrated a good response to treatment with high doses of cabergoline.
About the Authors
Zilya A. KalmykovaEndocrinology Research Centre
Russian Federation
MD, residence
Svetlana Y. Vorotnikova
Endocrinology Research Centre
Russian Federation
MD
Natalia S. Fedorova
Endocrinology Research Centre
Russian Federation
MD, PhD
Larisa K. Dzeranova
Endocrinology Research Centre
Russian Federation
MD, PhD
Ekaterina A. Pigarova
Endocrinology Research Centre
Russian Federation
MD, PhD
Aleksandr V. Vorontsov
Endocrinology Research Centre
Russian Federation
MD, PhD, professor
References
1. Colao A. The prolactinoma. Best Pract Res Clin Endocrinol Metab. 2009;23(5):575-596. doi: 10.1016/j.beem.2009.05.003
2. Gillam MP, Molitch ME, Lombardi G, Colao A. Advances in the Treatment of Prolactinomas. Endocr Rev. 2006;27(5):485-534. doi: 10.1210/er.2005-9998
3. Мельниченко Г.А., Дзеранова Л.К., Пигарова Е.А., и др. Федеральные клинические рекомендации по гиперпролактинемии: клиника, диагностика, дифференциальная диагностика и методы лечения. Проблемы эндокринологии. – 2013. – Т.59. – №6. – C.19-26. [Mel’nichenko GA, Dzeranova LK, Pigarova EA, et al. Russian association of endocrinologists national practice guidelines (clinical signs, diagnosis, differential diagnosis, treatment). Hyperprolactinemia. Problems of endocrinology. 2013;59(6):19-26. (In Russ.)] doi: 10.14341/probl201359619-26
4. Дзеранова Л.К., Федорова Н.С., Воротникова С.Ю., и др. Описание клинических портретов пациентов с гиперпролактинемией. Ожирение и метаболизм. – 2018. – Т.15. – №3. – C.65-69. [Dzeranova LK, Fedorova NS, Vorotnikova SY, et al. Description of clinical portraits of patients with hyperprolactinemia // Obesity and Metabolism. 2018;15(3):65-69. (In Russ.)] doi:10.14341/omet9866
5. Melmed S, Casanueva FF, Hoffman AR, et al. Diagnosis and Treatment of Hyperprolactinemia: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2011;96(2):273-288. doi: 10.1210/jc.2010-1692
6. Webster J, Piscitelli G, Polll A, et al. The efficacy and tolerability of long-term cabergoline therapy in hyperprolactinaemic disorders: an open, uncontrolled, multicentre study. Clin Endocrinol (Oxf). 1993;39(3):323-329. doi: 10.1111/j.1365-2265.1993.tb02372.x
7. Webster J, Piscitelli G, Polli A, Ferrari CI, Ismail I, Scanlon MF. A Comparison of Cabergoline and Bromocriptine in the Treatment of Hyperprolactinemic Amenorrhea. N Engl J Med. 1994;331(14):904-909. doi: 10.1056/NEJM199410063311403
8. SABUNCU T, ARIKAN E, TASAN E, HATEMI H. Comparison of the Effects of Cabergoline and Bromocriptine on Prolactin Levels in Hyperprolactinemic Patients. Intern Med. 2001;40(9):857-861. doi: 10.2169/internalmedicine.40.857
9. Федорова Н.С. Клинико-морфологическая характеристика пролактинсекретирующих опухолей гипофиза, резистентных к лечению агонистами дофамина: Диссертация на соискание ученой степени кандидата медицинских наук – Москва; 2018. [Fedorova NS. Kliniko-morfologicheskaya kharakteristika prolaktinsekretiruyushchikh opukholei gipofiza, rezistentnykh k lecheniyu agonistami dofamina. [dissertation] Moscow; 2018. (In Russ.)] Доступно по: https://www.endocrincentr.ru/sites/default/files/specialists/science/dissertation/avtoreferat_fedorova_v2.0.pdf
10. Vroonen L, Jaffrain-Rea M-L, Petrossians P, et al. Prolactinomas resistant to standard doses of cabergoline: a multicenter study of 92 patients. Eur J Endocrinol. 2012;167(5):651-662. doi: 10.1530/EJE-12-0236
11. Molitch ME. Management of medically refractory prolactinoma. J Neurooncol. 2014;117(3):421-428. doi: 10.1007/s11060-013-1270-8
12. Molitch ME. Pharmacologic Resistance in Prolactinoma Patients. Pituitary. 2005;8(1):43-52. doi: 10.1007/s11102-005-5085-2
13. Cannavò S, Bartolone L, Blandino A, et al. Shrinkage of a PRL-secreting pituitary macroadenoma resistant to cabergoline. J Endocrinol Invest. 1999;22(4):306-309. doi: 10.1007/BF03343561
14. Мельниченко Г.А., Дзеранова Л.К., Бармина И.И., и др. Резистентность ктерапии агонистами дофамина у пациентов с гиперпролактинемией // Вестник репродуктивного здоровья. –2007. – №1. – C.33-41. [Mel’nichenko GA, Dzeranova LK, Barmina II, et al. Rezistentnost’ k terapii agonistami dofamina u patsientov s giperprolaktinemiey // Bulletin of Reproductive Health 2007;(1):33-41 (In Russ.)] doi: 10.14341/brh2007133-41
15. Maiter D. Management of Dopamine Agonist-Resistant Prolactinoma. Neuroendocrinology. 2019;109(1):42-50. doi: 10.1159/000495775
16. Kissner DG, Jarrett JC. Side effects of bromocriptine. N Engl J Med. 1980;302(13):749-750. doi: 10.1056/NEJM198003273021313
17. Zanettini R, Antonini A, Gatto G, et al. Valvular Heart Disease and the Use of Dopamine Agonists for Parkinson’s Disease. Cohadon F, Dolenc V V, Antunes JL, et al., eds. N Engl J Med. 2007;356(1):39-46. doi: 10.1056/NEJMoa054830
18. Schade R, Andersohn F, Suissa S, et al. Dopamine Agonists and the Risk of Cardiac-Valve Regurgitation. N Engl J Med. 2007;356(1):29-38. doi: 10.1056/NEJMoa062222
19. Molitch ME. Drugs and prolactin. Pituitary. 2008;11(2):209-218. doi: 10.1007/s11102-008-0106-6
20. Bhatt MH, Keenan SP, Fleetham JA, Calne DB. Pleuropulmonary disease associated with dopamine agonist therapy. Ann Neurol. 1991;30(4):613-616. doi: 10.1002/ana.410300416
21. Frans E, Dom R, Demedts M. Pleuropulmonary changes during treatment of Parkinson’s disease with a long-acting ergot derivative, cabergoline. Eur Respir J. 1992;5(2):263-265. PMID: 1348483
22. Сапронова М.Р., Шнайдер Н.А. Предикторы и модификаторы импульсивно-компульсивных расстройств при болезни Паркинсона // Журнал неврологии и психиатрии. – 2016. –Т.116 – №11. – C.145 2016;116(11):145. [Sapronova MR., Schneider NA. Predictors and modifiers of impulsive compulsive disorders in Parkinson’s disease. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2016;116(11):145. (In Russ.)] doi: 10.17116/jnevro2016116111145-156
23. Vallelunga A, Flaibani R, Formento-Dojot P, Biundo R, Facchini S, Antonini A. Role of genetic polymorphisms of the dopaminergic system in Parkinson’s disease patients with impulse control disorders. Parkinsonism Relat Disord. 2012;18(4):397-399. doi: 10.1016/j.parkreldis.2011.10.019
24. Giladi N, Weitzman N, Schreiber S, Shabtai H, Peretz C. New onset heightened interest or drive for gambling, shopping, eating or sexual activity in patients with Parkinson’s disease: the role of dopamine agonist treatment and age at motor symptoms onset. J Psychopharmacol. 2007;21(5):501-506. doi: 10.1177/0269881106073109
25. Проскурина И.А., Романцова Т.И. Новые избирательные стимуляторы дофаминовых рецепторов в лечении гиперпролактинемического гипогонадизма. Международный журнал медицинской практики. – 2001. – №1. – C.36-46. [Proskurina IA, Romantsova TI. Novye izbiratel’nye stimulyatory dofaminovykh retseptorov v lechenii giperprolaktinemicheskogo gipogonadizma. Mezhdunarodnyi zhurnal meditsinskoi praktiki. 2001;(1):36-46 (In Russ.)]
26. Ono M, Miki N, Kawamata T, et al. Prospective Study of High-Dose Cabergoline Treatment of Prolactinomas in 150 Patients. J Clin Endocrinol Metab. 2008;93(12):4721-4727. doi: 10.1210/jc.2007-2758
27. Vilar L, Vilar C, Albuquerque JL, et al. The use of increasing doses of cabergoline in the management of cabergoline-resistant prolactinomas. Presented at 19th European Congress of Endocrinology May 2017, Lisbon, Portugal. Endocr Abstr. (2017)49EP975. doi: 10.1530/endoabs.49.EP975
28. Gillam MP, Middler S, Freed DJ, Molitch ME. The Novel Use of Very High Doses of Cabergoline and a Combination of Testosterone and an Aromatase Inhibitor in the Treatment of a Giant Prolactinoma. J Clin Endocrinol Metab. 2002;87(10):4447-4451. doi: 10.1210/jc.2002-020426
29. Delgrange E, Daems T, Verhelst J, et al. Characterization of resistance to the prolactin-lowering effects of cabergoline in macroprolactinomas: a study in 122 patients. Eur J Endocrinol. 2009;160(5):747-752. doi: 10.1530/EJE-09-0012
30. Di Sarno A, Landi ML, Cappabianca P, et al. Resistance to Cabergoline as Compared with Bromocriptine in Hyperprolactinemia: Prevalence, Clinical Definition, and Therapeutic Strategy. J Clin Endocrinol Metab. 2001;86(11):5256-5261. doi: 10.1210/jcem.86.11.8054
Supplementary files
|
|
1. Fig. 1. The dynamics of changes in the level of prolactin in serum during treatment with cabergoline | |
| Subject | ||
| Type | Исследовательские инструменты | |
View
(349KB)
|
Indexing metadata ▾ | |
|
|
2. Fig. 2. Change in the size and distribution of the formation of the pituitary gland after 5 years of therapy with cabergoline | |
| Subject | ||
| Type | Исследовательские инструменты | |
View
(814KB)
|
Indexing metadata ▾ | |
|
|
3. Рис. 2. Изменение размеров и распространения образования гипофиза через 5 лет терапии каберголином.(декабрь18)(декабрь13) | |
| Subject | ||
| Type | Исследовательские инструменты | |
View
(46KB)
|
Indexing metadata ▾ | |
Review
For citations:
Kalmykova Z.A., Vorotnikova S.Y., Fedorova N.S., Dzeranova L.K., Pigarova E.A., Vorontsov A.V. The efficacy of high-dose cabergoline treatment of prolactinomas resistant to standard doses: a clinical observation. Obesity and metabolism. 2019;16(2):89-94. (In Russ.) https://doi.org/10.14341/omet10243
Views:
5841
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
